
Nextcure (NXTC) Stock Forecast & Price Target
Nextcure (NXTC) Analyst Ratings
Bulls say
NextCure Inc. is focusing on innovative immunomedicines, with promising data from its lead candidates, particularly LNCB74, which has shown superior efficacy in preclinical models for oncology applications compared to similar constructs from competitors. The advances in NC605 for chronic bone diseases and NC181 for Alzheimer's disease have also demonstrated significant efficacy in preclinical models, indicating potential for impactful treatment options. Additionally, the ongoing patient enrollment in clinical trials for NC181 signals a positive safety profile, enhancing the company's growth prospects in the biopharmaceutical landscape.
Bears say
NextCure Inc. has faced a decrease in market confidence, highlighted by the termination of Pfizer's B7-H4 ADC program, which raises concerns about the viability of NextCure's LNCB74 candidate targeting the same pathway. Furthermore, the company has reported higher-than-expected operating expenses in the fourth quarter of 2024, prompting a reduction in price targets from $4 to $3. These factors collectively contribute to a pessimistic view of NextCure's financial outlook and future growth potential.
This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.
Nextcure (NXTC) Analyst Forecast & Price Prediction
Start investing in Nextcure (NXTC)
Order type
Buy in
Order amount
Est. shares
0 shares